Critical Outcome Tec (COTQF) 0.2280 $COTQF
Critical Outcome Technologies Reports Year-End Financial and Operating Results
Marketwire - Thu Jul 24, 3:21PM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT)(OTCQB: COTQF) reported its financial and operating results today for the fourth quarter and the year ended April 30, 2014 ("FYE 2014" .
Critical Outcome Technologies Inc. Announces Warrant Term Amendment
Marketwire - Wed Jul 16, 3:16PM CDT
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT)(OTCQB: COTQF) announced today that it is amending the expiry date of 3,569,458 common share purchase warrants (Warrants) issued as part of a non-brokered private placement on January 30, 2013, that were scheduled to expire on July 29, 2014. Each Warrant entitled its holder to purchase one common share of the Company at an exercise price of $0.26 per share for a period of 18 months from the date of issue.
Critical Outcome Technologies Seeks to Redefine Personalized Cancer Care With Project ROSALIND
Marketwire - Mon Jun 23, 8:05AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced today that Dr. Wayne Danter, President & CEO, will introduce "Project ROSALIND" in a podium presentation on June 25, 2014, at the annual BIO International Convention in San Diego California. The Company will use the hashtag #ROSALIND on Twitter for sharing more information with those not able to attend the presentation in person.
Critical Outcome Technologies Receives Orphan Drug Designation For COTI-2
Marketwire - Wed Jun 18, 1:30AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced today that the U.S. Food and Drug Administration (FDA) has granted COTI-2 an Orphan Drug Designation for the treatment of ovarian cancer.
Critical Outcome Technologies to Commence Trading in U.S. on OTCQB Under Symbol COTQF
Marketwire - Mon Jun 16, 8:03AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced that its common shares will commence trading today in the United States on the OTCQB venture stage marketplace under the symbol "COTQF."
Critical Outcome Technologies Inc.: SeeThruEquity Initiates Research Coverage
Marketwire - Fri Jun 13, 6:43PM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, is pleased to announce that SeeThruEquity, LLC ("SeeThruEquity" of New York, NY has initiated research coverage of COTI.
Critical Outcome Technologies Invited to Present at 16th International p53 Workshop in Sweden
Marketwire - Fri Jun 13, 8:01AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, announced today that its President and CEO, Dr. Wayne Danter, will be a featured presenter at the 16th International p53 Workshop at the Stockholm Waterfront Congress Centre in Sweden, which runs from June 15-19, 2014. This annual conference brings together world-renowned scientists to discuss novel, basic, transitional, and clinical research in the area of cancer biology with a focus on the p53 tumor suppressor gene.
Critical Outcome Technologies Inc. Completes Financing
Marketwire - Thu Jun 05, 2:07AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Corporation" the bioinformatics and accelerated drug discovery company, is pleased to announce the completion of the final tranche of its previously announced non-brokered private placement with the issuance of 5,595,135 units (the "Units" at a price of $0.16 per Unit for gross proceeds of approximately $895,000. In aggregate, the Corporation raised gross proceeds from the offering of approximately $1,432,000 through the sale of 8,951,385 Units.
Brain Cancer - Pipeline Review, H1 2014: 19 Companies Profiled
M2 - Thu May 29, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqsqp9/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope: - The report provides a snapshot of the global therapeutic landscape of Brain Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AngioChem Inc. - Basilea Pharmaceutica AG - Bionomics Limited - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals. LLC - DEKK-TEC, Inc. - EGEN, Inc. - Immune Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Merrimack Pharmaceuticals, Inc. - Neuralstem, Inc. - Nuvilex, Inc. - Oncology Research International Limited - Prana Biotechnology Limited - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - TVAX Biomedical, Inc. - e-Therapeutics plc - to-BBB technologies BV For more information visit http://www.researchandmarkets.com/research/hq...ain_cancer
Critical Outcome Technologies Selected to Present at Multiple Investor Conferences in New York City
Marketwire - Tue May 27, 8:03AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, will be a featured presenter at two upcoming microcap investor conferences in New York City. The Company will also be presenting at a dinner being held by the Financial Investment Analysts of New York on the evening of May 27th. In addition to providing a Company overview at all three events, President and CEO Dr. Wayne Danter's presentation will highlight the Company's lead cancer drug candidate, COTI-2, the opportunity to do R&D collaborations with CHEMSAS(R), and CHEMFirm, the Company's small molecule profiling and investment due diligence tool.
Critical Outcome Technologies Reports Year-End Financial and Operating Results
Marketwire - Thu Jul 24, 3:21PM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT)(OTCQB: COTQF) reported its financial and operating results today for the fourth quarter and the year ended April 30, 2014 ("FYE 2014" . Critical Outcome Technologies Inc. Announces Warrant Term Amendment
Marketwire - Wed Jul 16, 3:16PM CDT
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT)(OTCQB: COTQF) announced today that it is amending the expiry date of 3,569,458 common share purchase warrants (Warrants) issued as part of a non-brokered private placement on January 30, 2013, that were scheduled to expire on July 29, 2014. Each Warrant entitled its holder to purchase one common share of the Company at an exercise price of $0.26 per share for a period of 18 months from the date of issue.
Critical Outcome Technologies Seeks to Redefine Personalized Cancer Care With Project ROSALIND
Marketwire - Mon Jun 23, 8:05AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced today that Dr. Wayne Danter, President & CEO, will introduce "Project ROSALIND" in a podium presentation on June 25, 2014, at the annual BIO International Convention in San Diego California. The Company will use the hashtag #ROSALIND on Twitter for sharing more information with those not able to attend the presentation in person. Critical Outcome Technologies Receives Orphan Drug Designation For COTI-2
Marketwire - Wed Jun 18, 1:30AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced today that the U.S. Food and Drug Administration (FDA) has granted COTI-2 an Orphan Drug Designation for the treatment of ovarian cancer. Critical Outcome Technologies to Commence Trading in U.S. on OTCQB Under Symbol COTQF
Marketwire - Mon Jun 16, 8:03AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced that its common shares will commence trading today in the United States on the OTCQB venture stage marketplace under the symbol "COTQF." Critical Outcome Technologies Inc.: SeeThruEquity Initiates Research Coverage
Marketwire - Fri Jun 13, 6:43PM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, is pleased to announce that SeeThruEquity, LLC ("SeeThruEquity" of New York, NY has initiated research coverage of COTI. Critical Outcome Technologies Invited to Present at 16th International p53 Workshop in Sweden
Marketwire - Fri Jun 13, 8:01AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, announced today that its President and CEO, Dr. Wayne Danter, will be a featured presenter at the 16th International p53 Workshop at the Stockholm Waterfront Congress Centre in Sweden, which runs from June 15-19, 2014. This annual conference brings together world-renowned scientists to discuss novel, basic, transitional, and clinical research in the area of cancer biology with a focus on the p53 tumor suppressor gene. Critical Outcome Technologies Inc. Completes Financing
Marketwire - Thu Jun 05, 2:07AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Corporation"
the bioinformatics and accelerated drug discovery company, is pleased to announce the completion of the final tranche of its previously announced non-brokered private placement with the issuance of 5,595,135 units (the "Units" at a price of $0.16 per Unit for gross proceeds of approximately $895,000. In aggregate, the Corporation raised gross proceeds from the offering of approximately $1,432,000 through the sale of 8,951,385 Units. Brain Cancer - Pipeline Review, H1 2014: 19 Companies Profiled
M2 - Thu May 29, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqsqp9/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope: - The report provides a snapshot of the global therapeutic landscape of Brain Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AngioChem Inc. - Basilea Pharmaceutica AG - Bionomics Limited - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals. LLC - DEKK-TEC, Inc. - EGEN, Inc. - Immune Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Merrimack Pharmaceuticals, Inc. - Neuralstem, Inc. - Nuvilex, Inc. - Oncology Research International Limited - Prana Biotechnology Limited - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - TVAX Biomedical, Inc. - e-Therapeutics plc - to-BBB technologies BV For more information visit http://www.researchandmarkets.com/research/hq...ain_cancer
Critical Outcome Technologies Selected to Present at Multiple Investor Conferences in New York City
Marketwire - Tue May 27, 8:03AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, will be a featured presenter at two upcoming microcap investor conferences in New York City. The Company will also be presenting at a dinner being held by the Financial Investment Analysts of New York on the evening of May 27th. In addition to providing a Company overview at all three events, President and CEO Dr. Wayne Danter's presentation will highlight the Company's lead cancer drug candidate, COTI-2, the opportunity to do R&D collaborations with CHEMSAS(R), and CHEMFirm, the Company's small molecule profiling and investment due diligence tool. 
